USP8 and neoplasm: We observed that the USP8 inhibitor combined with αCTLA-4 group showed reductions compared with the control group in terms of tumor size and tumor weight, but these reductions were more significant in the USP8 inhibitor and αPD-L1 combination group (Fig. S12b, c).